This site is intended for healthcare professionals
Drug news

FDA extends review date of Uplyso (Pfizer)for Gauchers Disease until 1 May 2012

Read time: 1 mins
Last updated:7th Dec 2011
Published:7th Dec 2011
Source: Pharmawand
The FDA has extended its review by three months of the new drug application for Uplyso (taliglucerase alfa) from Pfizer/Protalix Biotherapeutics for the treatment of Gaucher's Disease .The effect delays the Prescription Drug User Fee Act action date until 1 May 2012. No additional data was requested by the FDA.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.